Multifunctional compounds: Smart molecules for multifactorial diseases

Shahin, 2012, Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials, Atherosclerosis, 221, 18, 10.1016/j.atherosclerosis.2011.12.005 Sata, 2011, Role of chronic inflammation in the pathogenesis of atherosclerosis, Nihon Yakurigaku Zasshi, 138, 182, 10.1254/fpj.138.182 Weber, 2011, Atherosclerosis: current pathogenesis and therapeutic options, Natural Medicines, 17, 1410, 10.1038/nm.2538 Lichtenstein, 2010, Staging anti-inflammatory therapy in alzheimer's disease, Frontiers in Aging Neuroscience, 2, 1, 10.3389/fnagi.2010.00142 Geldenhuys, 2011, The emergence of designed multiple ligands for neurodegenerative disorders, Progress in Neurobiology, 94, 347, 10.1016/j.pneurobio.2011.04.010 Zhang, 2005, One-compound-multiple-targets strategy to combat Alzheimer's disease, FEBS Letters, 579, 5260, 10.1016/j.febslet.2005.09.006 Van der Schyf, 2011, Multimodal drugs and their future for Alzheimer's and Parkinson's disease, International Review of Neurobiology, 100, 107, 10.1016/B978-0-12-386467-3.00006-6 Youdima, 2007, Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?, Parkinsonism & Related Disorders, 13, S281, 10.1016/S1353-8020(08)70017-8 Gella, 2009, Oxidative stress in Alzheimer disease, Cell Adhesion & Migration, 3, 88, 10.4161/cam.3.1.7402 Christen, 2000, Oxidative stress and Alzheimer disease, American Journal of Clinical Nutrition, 71, 621S, 10.1093/ajcn/71.2.621s Cirillo, 2009, Systemic inflammation, metabolic syndrome and progressive renal disease, Nephrology Dialysis Transplantation, 24, 1384, 10.1093/ndt/gfp038 McInnes, 2011, The pathogenesis of rheumatoid arthritis, The New England Journal of Medicine, 365, 2205, 10.1056/NEJMra1004965 Daoud, 1999, Basic therapy for rheumatoid arthritis: nonsteroidal anti-inflammatory drugs, Comprehensive Therapy, 25, 427, 10.1007/BF02944294 Volin, 2011, Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis, Journal of Interferon and Cytokine Research, 31, 745, 10.1089/jir.2011.0050 Kolahian, 2012, Cholinergic regulation of airway inflammation and remodelling, Journal of Allergy, 10.1155/2012/681258 Ozier, 2011, Pathophysiology of asthma, Revue du Praticien, 61, 339 Fireman, 2003, Understanding asthma pathophysiology, Allergy and Asthma Proceedings, 24, 79 Wang, 2011, Recent progress in understanding molecular mechanisms of cartilage degeneration during osteoarthritis, Annals of the New York Academy of Sciences, 1240, 61, 10.1111/j.1749-6632.2011.06258.x Malemud, 2010, Anticytokine therapy for osteoarthritis: evidence to date, Drugs & Aging, 27, 95, 10.2165/11319950-000000000-00000 Duddy, 2011, Managing MS in a changing treatment landscape, Journal of Neurology, 258, 728, 10.1007/s00415-011-6009-x Spain, 2009, Recent developments in multiple sclerosis therapeutics, BMC Medicine, 7, 74, 10.1186/1741-7015-7-74 Wang, 2010, Statins for multiple sclerosis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD008386.pub2 Dipiro, 2002 Sarantopoulos, 2007, Advances in the therapy of cancer pain: from novel experimental models to evidence-based treatments, Signa Vitae, 2, S 23, 10.22514/SV21.052007.4 Levy, 1996, Pharmacologic treatment of cancer pain, New England Journal of Medicine, 335, 1124, 10.1056/NEJM199610103351507 Targeted Cancer Therapies. National Cancer Institute. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted (accessed 10.01.13) Maggiora, 2011, The reductionist paradox: are the laws of chemistry and physics sufficient for the discovery of new drugs?, Journal of Computer-Aided Molecular Design, 25, 699, 10.1007/s10822-011-9447-8 Keith, 2005, Multicomponent therapeutics for networked systems, Nature Reviews Drug Discovery, 4, 71, 10.1038/nrd1609 Eisen, 1990, The effect of prescribed daily dose frequency on patient medical compliance, Archives of Internal Medicine, 25, 1881, 10.1001/archinte.1990.00390200073014 Hoh, 2001, Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department, Annals of Emergency Medicine, 38, 666, 10.1067/mem.2001.119456 Reddy, 2013, Polypharmacology: drug discovery for the future, Expert Review of Clinical Pharmacology, 6, 41, 10.1586/ecp.12.74 Morphy, 2004, From magic bullets to designed multiple ligands, Drug Discovery Today, 9, 641, 10.1016/S1359-6446(04)03163-0 Medina-Franco, 2013, Shifting from the single to the multitarget paradigm in drug discovery, Drug Discovery Today, 10.1016/j.drudis.2013.01.008 Morphy, 2005, Designed multiple ligands. An emerging drug discovery paradigm, Journal of Medicinal Chemistry, 48, 6523, 10.1021/jm058225d Cavalli, 2008, Multi-target-directed ligands to combat neurodegenerative diseases, Journal of Medicinal Chemistry, 51, 347, 10.1021/jm7009364 Youdim, 2005, CNS targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases, Journal of Neural Transmission, 112, 519, 10.1007/s00702-004-0214-z Youdim, 2005, Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders, Trends in Pharmacological Sciences, 26, 27, 10.1016/j.tips.2004.11.007 Buccafusco, 2009, Multifunctional receptor-directed drugs for disorders of the central nervous system, Neurotherapeutics, 6, 4, 10.1016/j.nurt.2008.10.031 Bolognesi, 2009, Alzheimer's disease: new approaches to drug discovery, Current Opinion in Chemical Biology, 13, 303, 10.1016/j.cbpa.2009.04.619 Minnerup, 2009, Multifunctional actions of approved and candidate stroke drugs, Neurotheraprutics: Journal of the American Society for Experimental NeuroTherapeutics, 6, 43, 10.1016/j.nurt.2008.10.032 Leon, 2013, Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease, Medicinal Research Reviews, 33, 139, 10.1002/med.20248 Lackey, 2012, The discovery of lapatinib, 181 Monzon, 2012, Combination agents versus multi-targeted agents – pros and cons, 155 Petrelli, 2008, From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage, Current Medicinal Chemistry, 15, 422, 10.2174/092986708783503212 Chen, 2013, Rationally designed multitarget anticancer agents, Current Medicinal Chemistry, 20, 1694, 10.2174/0929867311320130009 Liby, 2012, Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease, Pharmacological Reviews, 64, 972, 10.1124/pr.111.004846 Karoli, 2012, Structure aided design of chimeric antibiotics, Bioorganic & Medicinal Chemistry Letters, 22, 2428, 10.1016/j.bmcl.2012.02.019 Muregi, 2010, Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design, Drug Development Research, 71, 20 Gasco, 2008, Multitarget drugs: focus on the NO-donor hybrid drugs, Pure and Applied Chemistry, 80, 1693, 10.1351/pac200880081693 Liu, 2010, Synthesis and biological evaluation of novel leonurine-SPRC conjugate as cardioprotective agents, Bioorganic & Medicinal Chemistry Letters, 20, 6942, 10.1016/j.bmcl.2010.09.135 Huang, 2010, Synthesis, biological evaluation, and molecular modeling of berberine derivatives as potent acetylcholinesterase inhibitors, Bioorganic & Medicinal Chemistry, 18, 1244, 10.1016/j.bmc.2009.12.035 Jiang, 2011, Benzenediol-berberine hybrids: multifunctional agents for Alzheimer's disease, Bioorganic & Medicinal Chemistry, 19, 7228, 10.1016/j.bmc.2011.09.040 Tumiatti, 2010, Tacrine derivatives and Alzheimer's disease, Current Medicinal Chemistry, 17, 1825, 10.2174/092986710791111206 Dogterom, 1988, Hepatotoxicity of tetrahydroaminoacridine in isolated rat hepatocytes: effect of glutathione and vitamin E, Biochemical Pharmacology, 37, 2311, 10.1016/0006-2952(88)90356-5 Fernandez-Bachiller, 2010, Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties, Journal of Medicinal Chemistry, 53, 4927, 10.1021/jm100329q Galdeano, 2012, Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases, Journal of Medicinal Chemistry, 55, 661, 10.1021/jm200840c Camps, 2005, Synthesis and pharmacological evaluation of huprine-tacrine heterodimers: subnanomolar dual binding site acetylcholinesterase inhibitors, Journal of Medicinal Chemistry, 48, 1701, 10.1021/jm0496741 Fernandez-Bachiller, 2012, New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties, Journal of Medicinal Chemistry, 55, 1303, 10.1021/jm201460y Rosini, 2005, Rational approach to discover multipotent anti-Alzheimer's drugs, Journal of Medicinal Chemistry, 48, 360, 10.1021/jm049112h Rosini, 2011, Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease, European Journal of Medicinal Chemistry, 46, 5435, 10.1016/j.ejmech.2011.09.001 Wang, 2012, Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases, Journal of Medicinal Chemistry, 55, 3588, 10.1021/jm300124p Fang, 2008, Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer's drug candidates, Journal of Medicinal Chemistry, 51, 713, 10.1021/jm701491k Fang, 2008, NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity, Journal of Medicinal Chemistry, 51, 7666, 10.1021/jm801131a Franco, 2006, Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer's disease, with improved acetylcholinesterase inhibitory and antioxidant properties, Journal of Medicinal Chemistry, 49, 459, 10.1021/jm050746d Chao, 2012, Design, synthesis and pharmacological evaluation of novel tacrine-caffeic acid hybrids as multi-targeted compounds against Alzheimer's disease, Bioorganic & Medicinal Chemistry Letters, 22, 6498, 10.1016/j.bmcl.2012.08.036 Pi, 2012, Tacrine-6-Ferulic Acid, a novel multifunctional dimer, inhibits amyloid-β-mediated Alzheimer's disease-associated pathogenesis in vitro and in vivo, PLoS ONE, 7, e31921, 10.1371/journal.pone.0031921 Chen, 2012, Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo, Journal of Medicinal Chemistry, 55, 5231, 10.1021/jm300246n Lange, 2010, Design, synthesis, biological properties, and molecular modeling investigations of novel tacrine derivatives with a combination of acetylcholinesterase inhibition and cannabinoid CB1 receptor antagonism, Journal of Medicinal Chemistry, 53, 1338, 10.1021/jm901614b Fang, 2010, Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors, Journal of Medicinal Chemistry, 53, 2094, 10.1021/jm901616h Elsinghorst, 2007, First gallamine-tacrine hybrid: design and characterization at cholinesterases and the M2 muscarinic receptor, Journal of Medicinal Chemistry, 50, 5685, 10.1021/jm070859s Chen, 2012, Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors, Journal of Medicinal Chemistry, 55, 4309, 10.1021/jm300106z Walsh, 2007, A novel artemisnin–quinine hybrid with potent antimalarial activity, Bioorganic & Medicinal Chemistry Letters, 17, 3599, 10.1016/j.bmcl.2007.04.054 Cena, 2003, Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin, Journal of Medicinal Chemistry, 46, 747, 10.1021/jm020969t Hulsman, 2007, Chemical insights in the concept of hybrid drugs: the antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin, Journal of Medicinal Chemistry, 50, 2424, 10.1021/jm061371e Nemmani, 2009, NO-NSAIDs: gastric-sparing nitric oxide-releasable prodrugs of non-steroidal anti-inflammatory drugs, Bioorganic & Medicinal Chemistry Letters, 19, 5297, 10.1016/j.bmcl.2009.07.142 Nizri, 2005, Bifunctional compounds eliciting both anti-inflammatory and cholinergic activity as potential drugs for neuroinflammatory impairments, Neuroscience Letters, 376, 46, 10.1016/j.neulet.2004.11.030 Young, 2010, Peripheral site acetylcholinesterase inhibitors targeting both inflammation and cholinergic dysfunction, Bioorganic & Medicinal Chemistry Letters, 20, 2987, 10.1016/j.bmcl.2010.02.102 Doulgkeris, 2006, Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties, Bioorganic & Medicinal Chemistry Letters, 16, 825, 10.1016/j.bmcl.2005.11.027 Liu, 2009, Protective effects of leonurine in neonatal rat hypoxic cardiomyocytes and rat infarcted heart, Clinical and Experimental Pharmacology, 36, 696, 10.1111/j.1440-1681.2008.05135.x Loh, 2010, Leonurine protects middle cerebral artery occluded rats through antioxidant effect and regulation of mitochondrial function, Stroke, 41, 2661, 10.1161/STROKEAHA.110.589895 Wang, 2009, S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway, Journal of Cardiovascular Pharmacology, 54, 139, 10.1097/FJC.0b013e3181ac8e12 Liu, 2011, Leonurine-cysteine analog conjugates as a new class of multifunctional anti-myocardial ischemia agent, European Journal of Medicinal Chemistry, 46, 3996, 10.1016/j.ejmech.2011.05.073 Kim, 2005, Design and synthesis of new bis-pyridinium oxime reactivators for acetylcholinesterase inhibited by organophosphorous nerve agents, Bioorganic & Medicinal Chemistry Letters, 15, 2914, 10.1016/j.bmcl.2005.03.060 Antonijevic, 2007, Unequal efficacy of pyridinium oximes in acute organophosphate poisoning, Clinical Medicine & Research, 5, 71, 10.3121/cmr.2007.701 Lovric, 2011, A conjugate of pyridine-4-aldoxime and atropine as a potential antidote against organophosphorus compounds poisoning, Acta Biochimica Polonica, 58, 193, 10.18388/abp.2011_2264 Weissman, 2011, Multifunctional drugs as novel antidotes for organophosphates' poisoning, Toxicology, 290, 149, 10.1016/j.tox.2011.09.004 Buchanan, 1996, Fluoxetine augmentation of clozapine treatment in patients with schizophrenia, American Journal of Psychiatry, 153, 1625, 10.1176/ajp.153.12.1625 Centorrino, 1996, Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors, American Journal of Psychiatry, 153, 820, 10.1176/ajp.153.6.820 Smid, 2005, Synthesis, structure-activity relationships, and biological properties of 1-heteroaryl-4-[o-(1H-indol-3-yl)alkyl]piperazines, novel potential antipsychotics combining potent dopamine D2 receptor antagonism with potent serotonin reuptake inhibition, Journal of Medicinal Chemistry, 48, 6855, 10.1021/jm050148z Weinreb, 2009, Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs, Neurotherapeutics: the American Society for Experimental NeuroTherapeutics, 6, 163, 10.1016/j.nurt.2008.10.030 Zheng, 2009, Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy, Journal of Medicinal Chemistry, 52, 4095, 10.1021/jm900504c Reinke, 2007, Structure–activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility, Chemical Biology & Drug Design, 70, 206, 10.1111/j.1747-0285.2007.00557.x Chen, 2011, Design, synthesis, and biological evaluation of curcumin analogues as multifunctional agents for the treatment of Alzheimer's disease, Bioorganic & Medicinal Chemistry, 19, 5596, 10.1016/j.bmc.2011.07.033 Camps, 2000, New tacrine-huperzine A hybrids (Huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease, Journal of Medicinal Chemistry, 43, 4657, 10.1021/jm000980y Camps, 1999, Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine a hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease, Journal of Medicinal Chemistry, 42, 3227, 10.1021/jm980620z Marco-Contelles, 2006, Novel multipotent tacrine-dihydropyridine hybrids with improved acetylcholinesterase inhibitory and neuroprotective activities as potential drugs for the treatment of Alzheimer's disease, Journal of Medicinal Chemistry, 49, 7607, 10.1021/jm061047j Contelles, 2009, Tacripyrines, the first tacrine-dihydropyridine hybrids, as multitarget-directed ligands for the treatment of Alzheimer's disease, Journal of Medicinal Chemistry, 52, 2724, 10.1021/jm801292b Juranek, 2010, Antioxidants in treating pathologies involving oxidative damage: an update on medicinal chemistry and biological activity of stobadine and related pyridoindoles, Current Medicinal Chemistry, 17, 552, 10.2174/092986710790416317 Stefek, 2011, (2-Benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-8-yl)-acetic acid: an aldose reductase inhibitor and antioxidant of zwitterionic nature, Bioorganic & Medicinal Chemistry, 19, 7181, 10.1016/j.bmc.2011.09.053 Elsayed, 2008, Emerging lipid-lowering drugs: squalene synthase inhibitors, Expert Opinion on Emergency Drugs, 13, 309, 10.1517/14728214.13.2.309 Kourounakis, 2008, Lipid-lowering (hetero)aromatic tetrahydro-1,4-oxazine derivatives with antioxidant and squalene synthase inhibitory activity, Journal of Medicinal Chemistry, 51, 5861, 10.1021/jm800663w Kourounakis, 2010, Design of more potent squalene synthase inhibitors with multiple activities, Bioorganic & Medicinal Chemistry, 18, 7402, 10.1016/j.bmc.2010.09.008 Van der Schyf, 2009, Polycyclic compounds: Ideal drug scaffolds for the design of multiple mechanism drugs, Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics, 6, 175, 10.1016/j.nurt.2008.10.037 Thomas, 2001, High-affinity blockade of human ether-a-go-go-related gene human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872, Journal of Pharmacology and Experimental Therapeutics, 297, 753 Geldenhuys, 2007, Structure-activity relationships of pentacycloundecylamines at the N-methyl-D-aspartate receptor, Bioorganic & Medicinal Chemistry, 15, 1525, 10.1016/j.bmc.2006.09.060 Geldenhuys, 2003, Screening of novel pentacycloundecylamines for neuroprotective activity, European Journal of Pharmacology, 458, 73, 10.1016/S0014-2999(02)02701-2 Kornhuber, 1993, Affinity of 1-aminoadamantanes for the sigma binding site in post-mortem human frontal cortex, Neuroscience Letters, 163, 129, 10.1016/0304-3940(93)90362-O Liu, 2007, Trishomocubanes: novel sigma ligands modulate cocaine-induced behavioural effects, European Journal of Pharmacology, 555, 37, 10.1016/j.ejphar.2006.10.020 Oliver, 1991, Synthesis and biological activity of D3-trishomocubyl-4-amines, Journal of Medicinal Chemistry, 34, 851, 10.1021/jm00106a053 Oliver, 1991, Antiviral properties of 4-amino-(D3)-trishomocubanes, Arzneimittelforschung, 41, 549 Bezuidenhout, 2007, Polycyclic amine derivatives: the synthesis of triquinylamines as calcium modulators Joubert, 2011, Synthesis and evaluation of fluorescent heterocyclic aminoadamantanes as multifunctional neuroprotective agents, Bioorganic & Medicinal Chemistry, 19, 3935, 10.1016/j.bmc.2011.05.034